Academia Strategic Alliances: Modeling for Success

Dr. Bill Dalton, M2Gen

Dr. Bill Dalton serves as Founder & CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. Before taking this role, he was the President & CEO of Moffitt Cancer Center from 2002 to 2012. He currently serves as the President of the Association of American Cancer Institutes, Chairs the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research, as well as serves on the Institute of Medicine’s National Cancer Policy Forum and various NCI, cancer center and research foundation scientific advisory boards across the U.S. In addition, Dr. Dalton serves at the state level as a member of the Florida Council of 100, an advisory role to the Governor, the Chief Justice, the Legislature, as well as private organizations, to promote the economic growth of Florida and improve the economic well-being and quality of life of the citizens of Florida.

Healthcare Startups for the Tech Savvy

Edward Chwieseni, Moffitt Cancer Center

Edward Chwieseni is the Director of IT for Moffitt Cancer Center and its wholly owned subsidiary M2Gen. He is responsible for IT strategy, planning and implementation efforts at Moffitt and M2Gen, including software development, data warehousing, project management, clinical trials systems, research IT projects and IT infrastructure and has over 28 years of experience working in IT. Before joining the Moffitt group, Mr. Chwieseni held multiple senior (CIO, CTO, and CTIO) positions at a number of early stage companies. Mr. Chwieseni has a BS (Hons) Computer Science from Teesside, an MBA from Phoenix, and is currently working on his PhD.

Collaborative Diagnosis: Patient Genomic Information

Dr. Howard McLeod, Moffitt Cancer Center

Howard McLeod, Pharm.D., is an internationally recognized expert in how genetic makeup affects an individual’s response to cancer treatment. He joined Moffitt Cancer Center as the new medical director of the DeBartolo Family Personalized Medicine Institute and senior member in the Department of Cancer Epidemiology. McLeod has been principal investigator for more than $16 million in grants and co-investigator for more than $80 million in grants from the National Institutes of Health. He has also authored more than 450 peer-reviewed papers on pharmacogenomics, applied therapeutics and clinical pharmacology.

Raising Funds: What’s Trending Now

Julio C. Esquivel, J.D., Shumaker, Loop, & Kendrick, LLP

Julio C. Esquivel, J.D. is a partner at the law firm of Shumaker, Loop, & Kendrick, LLP. Julio is a member of the Firm’s Management Committee and has significant experience in corporate, transactional and securities matters, including: public offerings and private placements; domestic and international mergers and acquisitions; recapitalization and restructurings; venture capital; joint ventures; franchising; and Securities Exchange Act reporting obligations. Julio received his Bachelor of Science degree in Finance from the University of Florida in 1988 and his Juris Doctorate from the University of California at Berkeley School of Law (Boalt Hall) in 1991.